A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1  

作　　者：Kangyin Li Qi Liu Yan Wu Bihao Wu Shaohong Chen Xinghai Zhang Xiaoying Jia Rui Gong Yucai Peng Huajun Zhang Sandra Chiu 

机构地区：[1]Key Laboratory of Virology and Biosafety,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan,430062,China [2]University of Chinese Academy of Sciences,Beijing,100049,China [3]Liverna Therapeutics Inc.,Zhuhai,519000,China [4]Division of Life Sciences and Medicine,University of Science and Technology of Chin1,Hefei,230027,China [5]Department of Laboratory Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of Chin1,Hefei,230027,China [6]Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases,Hefei,230027,China

出　　处：《Virologica Sinica》2024年第5期833-835,共3页中国病毒学（英文版）

摘　　要：Dear Editor,The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has posed a continuous threat to global public health.A number of vaccines,such as inactivated vaccines,mRNA vaccines,recombinant adenovirus vector vaccines and protein subunit vaccines,have been licensed and have achieved tremendous success in preventing infections,particularly severe hospitalization and death(Feikin et al.,2022;Ssentongo et al.,2022).However,with the emergence of new variants,breakthrough infections have occurred among vaccines,highlighting the need to develop broad-spectrum vaccines(Ukwishaka et al.,2023).

关 键 词：acute RESPIRATORY 

分 类 号：R392-33[医药卫生—免疫学]